Skip to main content
main-content

06-06-2011 | Cardiometabolic | Article

Fibrates reduce CV risk in dyslipidemic patients

Abstract

Free abstract

MedWire News: Fibrate treatment is effective for reducing cardiovascular risk in patients with atherogenic dyslipidemia, a meta-analysis of published studies suggests.

Specifically, the team found that fibrate therapy was associated with a 16% to 29% reduction in vascular risk in these patients.

"The effect was most pronounced in persons with presence of both elevated serum triglycerides and reduced high-density lipoprotein (HDL) cholesterol levels," write Bruce Ovbiagele (University of California, San Diego, USA) and colleagues in the journal Atherosclerosis.

The researchers' systematic review and meta-analysis included six studies involving patients with atherogenic dyslipidemia (serum HDL cholesterol <40 mg/dl [1.04 mmol/l] or triglycerides >200 mg/dl [2.26 mmol/l]).

Ovbiagele et al report a significant 29% reduction in risk for vascular events (defined as the composite of nonfatal myocardial infarct, nonfatal stroke, and vascular death) among patients with hypertriglyceridemia and low HDL-cholesterol (n=5068) who were using fibrates, compared with placebo.

Among patients with either hypertriglyceridemia (n=7389) or low HDL cholesterol (n=15,303), fibrate use was associated with a 25% and 16% reduction in vascular event risk, respectively, compared with placebo.

Fibrates had no significant effect in reducing vascular risk in patients who did not have atherogenic dyslipidemia, notes the team.

Ovbiagele and co-authors say: "Our results further reinforce the [National Cholesterol Education Program] Adult Treatment Panel III guidelines which stress the importance of incorporating targeted modification of elevated serum triglycerides and low HDL cholesterol levels as part of an optimal vascular risk reduction strategy."

They suggest that, to substantially reduce future vascular events, fibrate treatment should be directed at patients who present with markers of atherogenic dyslipidemia.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011

By Nikki Withers